Currently, treatment of patients with CKD at risk for heart failure includes angiotensin-converting enzyme inhibitors or angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and, more recently, sodium-glucose transporter-2 inhibitors. The gene discussed is ACE; the disease is chronic kidney disease.